Title:
The antibody combined with phosphorylcholine (PC) and/or PC conjugate
Document Type and Number:
Japanese Patent JP6277126
Kind Code:
B2
Abstract:
The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein—(a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of:a CDR1 sequence comprising an amino acid sequence having at least 20%, 40%, 60%, 80% or 100% sequence identity to the sequence of SEQ ID NO: 7;a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 41%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 88%, 94%, or 100% sequence identity to the sequence of SEQ ID NO: 8; anda CDR3 sequence comprising an amino acid sequence having at least 11%, 22%, 33%, 44%, 55%, 66%, 77%, 88% or 100% sequence identity to the sequence of SEQ ID NO: 9 or 10; and/or(b) the VL domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of:a CDR4 sequence comprising an amino acid sequence having at least 7.5%, 15%, 23%, 30%, 38%, 46%, 53%, 61%, 69%, 76%, 84%, 92% or 100% sequence identity to the sequence of SEQ ID NO: 11;a CDR5 sequence comprising an amino acid sequence having at least 14%, 28%, 42%, 57%, 71%, 85% or 100% sequence identity to the sequence of SEQ ID NO: 12;a CDR6 sequence comprising an amino acid sequence having at least 9%, 18%, 27%, 36%, 45%, 54%, 63%, 72%, 81%, 90% or 100% sequence identity to the sequence of SEQ ID NO: 13.
Inventors:
Knut Petterson
Ora Camber
Dan Sexton
Andrew E Nixon
Ora Camber
Dan Sexton
Andrew E Nixon
Application Number:
JP2014525119A
Publication Date:
February 07, 2018
Filing Date:
August 08, 2012
Export Citation:
Assignee:
Asera Biotechnology Arb
Diax corporation
Diax corporation
International Classes:
C12N15/09; A61K39/395; A61P3/00; A61P3/06; A61P3/10; A61P9/10; A61P25/28; A61P37/02; C07K16/00; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12P21/08
Domestic Patent References:
| JP2009095346A | ||||
| JP2008515774A | ||||
| JP2008501636A |
Foreign References:
| WO2010003602A1 | ||||
| WO2006110831A1 |
Other References:
EWING MARK,CIRCULATION [ONLINE],米国,LIPPINCOTT WILLIAMS & WILKINS,2010年11月23日,V122 N21 SUPPL.S,P A14320,URL,http://circ.ahajournals.org/
S.Horkko, et al., J Clin Invest., 1999, 103(1), pp117-128
M.K.Chang, et al., Proc Natl Acad Sci., 1999, 96, pp6353-6358
Ulf de Faire, et al., Annals of the New York Academy of Sciences, 2009, 1173, pp292-300
Carina Schmidt, Out-licensing: 'A Start-up Company Perspective', Eurobio in Lille, France, Sept 24 2009, [retrieved on 2016.8.24]. Retrieved from the Internet,URL,www.eurobio-event.com/DocBD/speaker/pdf/64.pdf
W.Palinski, et al., J Clin Invest., 1996, 98, pp800-814
S.Horkko, et al., J Clin Invest., 1999, 103(1), pp117-128
M.K.Chang, et al., Proc Natl Acad Sci., 1999, 96, pp6353-6358
Ulf de Faire, et al., Annals of the New York Academy of Sciences, 2009, 1173, pp292-300
Carina Schmidt, Out-licensing: 'A Start-up Company Perspective', Eurobio in Lille, France, Sept 24 2009, [retrieved on 2016.8.24]. Retrieved from the Internet,URL,www.eurobio-event.com/DocBD/speaker/pdf/64.pdf
W.Palinski, et al., J Clin Invest., 1996, 98, pp800-814
Attorney, Agent or Firm:
Yasuhiko Murayama
Shinya Mitsuhiro
Tatsuhiko Abe
Shinya Mitsuhiro
Tatsuhiko Abe